RE: Full Case Study Document AVA61038 Feb 2025 10:53
i don’t think people are quite grasping the full potential here when talking about time to peak sales etc .
why would you use a drug or a version of a drug, ie adcs , when there is a non toxic version of that same drug giving superior results. overnight avacta platform could become the standard of care.
how can you make estimates on drug sales based on existing data about a given drug when the ava range have no mtd , ie given higher doses over longer period. ava6000 alone is mind blowing , given the scale of dosing so fr, with dox at 1bil pa sales to date. even a *** backer calculation will tell you this is off the scale if it gets to market.